LYTAC-mediated Degradation of Key Proteins in Hepatocellular Carcinoma and its Potential Clinical Application

Lysosome-Targeting Chimeras (LYTAC) technology, with its unique mechanisms and advantages, can efficiently and specifically degrade intracellular, extracellular, and membrane proteins, offering a novel approach for hepatocellular carcinoma (HCC) treatment. This article reviews LYTAC-mediated degradation strategies targeting key proteins in HCC and their potential clinical applications. LYTAC technology employs targeting ligands to bind critical HCC proteins and directs them to lysosomes for degradation. Research has shown that this technology can effectively degrade key proteins such as heparanase (HPA1) and the epidermal growth factor receptor (EGFR), thereby inhibiting tumor cell proliferation, invasion, and metastasis while enhancing immune cell recognition and cytotoxicity against tumors. Furthermore, LYTAC technology can be combined with immunotherapy, chemotherapy, and other treatments to improve drug targeting, modulate the tumor microenvironment, and facilitate personalized medicine approaches.